377740.KO BioNote Inc.
- Market cap
- KRW 475B
- P/E
- -
- P/B
- 0.31x
- ROE
- 6.5%
- Dividend yield
- 4.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 377740.KO undervalued?
Graham numberThe Graham number of BioNote Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioNote Inc. fundamental analysis
No fundamental analysis for BioNote Inc. yet.
BioNote Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioNote Inc.
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents. In addition, it engages in the production and sell of medical…
Full company profileBioNote Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioNote Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 40.0B | 632B | 622B | 480B | 90.1B | 103B | 118B | 138B |
| Gross Profit | 18.7B | 580B | 512B | 341B | -11.6B | 51.2B | 65.8B | 77.4B |
| Operating Income | 9.93B | 558B | 469B | 295B | -47.0B | 12.2B | 16.8B | 29.6B |
| EBITDA | 27.1B | 697B | 870B | 421B | -101B | 81.7B | -78.1B | 146B |
| Net Income | 20.6B | 528B | 677B | 308B | -20.5B | 55.3B | -87.5B | 101B |
| EPS | 198 | 5,081 | 6,641 | 3,021 | -201 | 545 | -867 | 1,000 |
| Balance Sheet | ||||||||
| Total Assets | 131B | 853B | 1.49T | 1.76T | 1.59T | 1.70T | 1.56T | 1.61T |
| Total Liabilities | 20.3B | 215B | 216B | 157B | 36.3B | 61.4B | 44.6B | 63.5B |
| Shareholders' Equity | 111B | 639B | 1.27T | 1.60T | 1.56T | 1.64T | 1.51T | 1.55T |
| Cash & Short-term Investments | 6.58B | 123B | 419B | 681B | 147B | 107B | 17.9B | 56.6B |
| Cash Flow | ||||||||
| Operating Cash Flow | 9.85B | 240B | 537B | 249B | -4.19B | 57.9B | 14.4B | 70.9B |
| Capital Expenditure | 1.53B | 26.7B | 51.5B | 42.5B | 4.54B | 10.5B | 8.27B | 3.60B |
| Free Cash Flow | 8.32B | 213B | 486B | 207B | -8.74B | 47.4B | 6.11B | 67.3B |
| Ratios | ||||||||
| ROE | 18.6% | 82.7% | 53.2% | 19.2% | -1.3% | 3.4% | -5.8% | 6.5% |
| ROA | 15.8% | 61.9% | 45.4% | 17.5% | -1.3% | 3.3% | -5.6% | 6.2% |
| Net Profit Margin | 51.5% | 83.6% | 108.7% | 64.2% | -22.8% | 53.8% | -73.9% | 73.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioNote Inc. dividends
- Dividend yield
- 4.27%
- Forward dividend
- 228.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 20.3B | 201 | - |
| 2024 | KRW 20.4B | 201 | 36.9% |
| 2023 | KRW 49.9B | 489 | - |
| 2022 | KRW 50.0B | 490 | 16.2% |
| 2021 | KRW 50.0B | 490 | 7.4% |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BioNote Inc.
- Insiders 80.21%
- Institutions 5.96%
- Public & others 13.83%
- Shares outstanding 101M
- Free float 13.2M
BioNote Inc. company profile
- Company name
- BioNote Inc.
- Ticker
- 377740.KO
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 299
- Fiscal year end
- December
- Address
- 22, Samsung 1-ro 4-gil, Hwaseong-si, South Korea
- Phone
- 82 3 1211 0516
- Website
- bionote.co.kr
About BioNote Inc.
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents. In addition, it engages in the production and sell of medical devices. BioNote, Inc. was founded in 2003 and is headquartered in Hwaseong-si, South Korea.
BioNote Inc. management
10- Mr. ByungKi ChoCEO & Representative Director · born 1967
- Mr. GukMyeong LeeMD & CFO · born 1972
- Ms. GeumYoung OhSenior Accounting Manager
- Mr. JeongHwan LimExecutive Director and GM of Management Headquarters & Legal Department · born 1971
- Mr. JeongHo KimExecutive Director · born 1976
- Ms. Hyeim ChoHead of Marketing Strategy Office & Executive Director · born 1987
- Mr. JuHwan SungMD & GM of Operations Support Office · born 1973
- Mr. IlJung KimExecutive Director · born 1976
- Mr. MyoungKyu ChungHead of Diagnostic Reagent Production Division · born 1983
- Mr. SangYoung JeongMD & Head of New Drug Development Business Division · born 1977